Advertisement

Molecular and Cellular Biochemistry

, Volume 404, Issue 1–2, pp 181–191 | Cite as

Alterations in gene promoter methylation and transcript expression induced by cisplatin in comparison to 5-Azacytidine in HeLa and SiHa cervical cancer cell lines

  • Swati Sood
  • Radhika Srinivasan
Article

Abstract

Despite recent advances in treatment, cervical cancer still remains one of the leading causes of cancer related mortality among women worldwide including India. Chemoradiation treatment is the standard-of-care which involves administration of cisplatin, a radiosensitizer along with radiation. The epigenetic changes induced by cisplatin are not known and so we designed this in vitro experimental study. We evaluated the changes induced by cisplatin administration in gene promoter methylation and the transcript levels of set of 7 genes and compared it to the changes induced by 5-Azacytidine, a known demethylating agent in two cervical cancer cell lines: HeLa (adenocarcinoma derived) and SiHa (squamous cell carcinoma derived) cell lines. Overall, there was a pronounced cytotoxic and growth inhibitory effect of both the drugs alone and in combination for both the cell lines which was dose and time dependent. Cisplatin as well as 5-Azacytidine treatment affected gene promoter methylation status resulting in demethylation and re-expression of the genes under investigation which was more pronounced in case of SiHa cells as compared to HeLa cells. Further, both the drugs acted in synergism as evident from their combination treatment. Therefore, at the cellular level, cisplatin and 5-Azacytidine can induce epigenetic changes in gene promoter methylation with altered expression which can have implications for treatment of cervical cancer.

Keywords

Cisplatin 5-Azacytidine Methylation Transcript expression SiHa HeLa 

Notes

Acknowledgments

This study was supported financially by Indian Council of Medical Research (ICMR), New Delhi India vide Grant No. 5/13/79/06/NCD-III.

Compliance with Ethical Standards

The authors have no conflict of Interest or financial disclosures to declare. The study does not involve human participants and/or animals. It is solely carried out on cell lines. Hence informed consent is not applicable. The study has been carried out in accordance with the Institute ethics committee guidelines.

Supplementary material

11010_2015_2377_MOESM1_ESM.docx (19 kb)
Supplementary material 1 (DOCX 19 kb)

References

  1. 1.
    Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM (2010) Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 127:2893–2917CrossRefPubMedGoogle Scholar
  2. 2.
    Sarkar S, Horn G, Moulton K, Oza A, Byler S, Kokolus S et al (2013) Cancer development, progression, and therapy: an epigenetic overview. Int J Mol Sci 14:21087–21113CrossRefPubMedCentralPubMedGoogle Scholar
  3. 3.
    Kulis M, Esteller M (2010) DNA methylation and cancer. Adv Genet 70:27–56CrossRefPubMedGoogle Scholar
  4. 4.
    Bhatt AN, Mathur R, Farooque A, Verma A, Dwarakanath B (2010) Cancer biomarkers-current perspectives. Indian J Med Res 132:129–149PubMedGoogle Scholar
  5. 5.
    Goffin J, Eisenhauer E (2002) DNA methyltransferase inhibitors—state of the art. Ann Oncol 13:1699–1716CrossRefPubMedGoogle Scholar
  6. 6.
    Balch C, Yan P, Craft T, Young S, Skalnik DG, Huang TH et al (2005) Antimitogenic and chemosensitizing effects of the methylation inhibitor zebularine in ovarian cancer. Mol Cancer Ther 4:1505–1514CrossRefPubMedGoogle Scholar
  7. 7.
    Macciò A, Madeddu C (2013) Cisplatin: an old drug with a newfound efficacy-from mechanisms of action to cytotoxicity. Expert Opin Pharmacother 14:1839–1857CrossRefPubMedGoogle Scholar
  8. 8.
    Mueller S, Schittenhelm M, Honecker F, Malenke E, Lauber K, Wesselborg S et al (2006) Cell-cycle progression and response of germ cell tumors to cisplatin in vitro. Int J Oncol 29:471PubMedGoogle Scholar
  9. 9.
    Fuertes MA, Alonso C, Pérez JM (2003) Biochemical modulation of cisplatin mechanisms of action: enhancement of antitumor activity and circumvention of drug resistance. Chem Rev 103:645–662CrossRefPubMedGoogle Scholar
  10. 10.
    Dong SM, Kim HS, Rha SH, Sidransky D (2001) Promoter hypermethylation of multiple genes in carcinoma of the uterine cervix. Clin Cancer Res 7:1982–1986PubMedGoogle Scholar
  11. 11.
    Zhai Y, Bommer GT, Feng Y, Wiese AB, Fearon ER, Cho KR (2010) Loss of estrogen receptor 1 enhances cervical cancer invasion. Am J Pathol 177:884–895CrossRefPubMedCentralPubMedGoogle Scholar
  12. 12.
    Cohen Y, Singer G, Lavie O, Dong SM, Beller U, Sidransky D (2003) The RASSF1A tumor suppressor gene is commonly inactivated in adenocarcinoma of the uterine cervix. Clin Cancer Res 9:2981–2984PubMedGoogle Scholar
  13. 13.
    Yu MY, Tong JH, Chan PK, Lee TL, Chan MW, Chan AW et al (2003) Hypermethylation of the tumor suppressor gene RASSFIA and frequent concomitant loss of heterozygosity at 3p21 in cervical cancers. Int J Cancer 105:204–209CrossRefPubMedGoogle Scholar
  14. 14.
    Widschwendter A, Muller HM, Fiegl H, Ivarsson L, Wiedemair A, Muller-Holzner E, Goebel G, Marth C, Widschwendter M (2004) DNA methylation in serum and tumors of cervical cancer patients. Clin Cancer Res 10:565–571CrossRefPubMedGoogle Scholar
  15. 15.
    Kang S, Kim JW, Kang GH, Park NH, Song YS, Kang SB et al (2005) Polymorphism in folate-and methionine-metabolizing enzyme and aberrant CpG island hypermethylation in uterine cervical cancer. Gynecol Oncol 96:173–180CrossRefPubMedGoogle Scholar
  16. 16.
    Narayan G, Arias-Pulido H, Nandula SV, Basso K, Sugirtharaj DD, Vargas H et al (2004) Promoter hypermethylation of FANCF disruption of Fanconi Anemia-BRCA pathway in cervical cancer. Cancer Res 64:2994–2997CrossRefPubMedGoogle Scholar
  17. 17.
    Wisman GB, Knol AJ, Helder MN, Krans M, de Vries EG, Hollema H et al (2001) Telomerase in relation to clinicopathologic prognostic factors and survival in cervical cancer. Int J Cancer 91:658–664CrossRefPubMedGoogle Scholar
  18. 18.
    Herman JG, Graff JR, Myohanen S, Nelkin BD, Baylin SB (1996) Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci U S A 93:9821–9826CrossRefPubMedCentralPubMedGoogle Scholar
  19. 19.
    Yu J, Zhang H, Gu J, Lin S, Li J, Lu W, Wang Y, Zhu J (2004) Methylation profiles of thirty four promoterCpG islands and concordant methylation behaviours of sixteen genes that may contribute to carcinogenesis of astrocytoma. BMC Cancer 4:65CrossRefPubMedCentralPubMedGoogle Scholar
  20. 20.
    Momparler RL (2003) Cancer epigenetics. Oncogene 22:6479–6483CrossRefPubMedGoogle Scholar
  21. 21.
    Christman JK (2002) 5-Azacytidine and 5-aza-2’-deoxycytidine as inhibitors of DNA methylation: mechanistic studies and their implications for cancer therapy. Oncogene 21:5483–5495CrossRefPubMedGoogle Scholar
  22. 22.
    Schaefer M, Hagemann S, Hanna K, Lyko F (2009) Azacytidine inhibits RNA methylation at DNMT2 target sites in human cancer cell lines. Cancer Res 69:8127–8132CrossRefPubMedGoogle Scholar
  23. 23.
    Jacobs AJ, Dawoud L, Kovacs Z, Ratliff TL (1989) Inhibition of proliferation of lines derived from human cervical carcinomas by cytotoxic drugs and by recombinant interferons. Gynecol Oncol 32:31–36CrossRefPubMedGoogle Scholar
  24. 24.
    Venkatraman M, Anto RJ, Nair A, Varghese M, Karunagaran D (2005) Biological and chemical inhibitors of NF-κB sensitize SiHa cells to cisplatin-induced apoptosis. Mol Carcinog 44:51–59CrossRefPubMedGoogle Scholar
  25. 25.
    Alexander VM, Roy M, Steffens KA, Kunnimalaiyaan M, Chen H (2010) Azacytidine induces cell cycle arrest and suppression of neuroendocrine markers in carcinoids. Int J Clin Expl Med 3:95Google Scholar
  26. 26.
    Schneider-Stock R, Diab-Assef M, Rohrbeck A, Foltzer-Jourdainne C, Boltze C, Hartig R et al (2005) 5-Aza-cytidine is a potent inhibitor of DNA methyltransferase 3a and induces apoptosis in HCT-116 colon cancer cells via Gadd45-and p53-dependent mechanisms. J Pharmacol Exp Ther 312:525–536CrossRefPubMedGoogle Scholar
  27. 27.
    Sova P, Feng Q, Geiss G, Wood T, Strauss R, Rudolf V et al (2006) Discovery of novel methylation biomarkers in cervical carcinoma by global demethylation and microarray analysis. Cancer Epidemiol Biomarkers Prev 15:114–123CrossRefPubMedGoogle Scholar
  28. 28.
    Koul S, McKiernan J, Narayan G, Houldsworth J, Bacik J, Dobrzynski D et al (2004) Role of promoter hypermethylation in Cisplatin treatment response of male germ cell tumors. Mol Cancer 3:16CrossRefPubMedCentralPubMedGoogle Scholar
  29. 29.
    Yoo HJ, Byun HJ, Kim BR, Lee KH, Park SY, Rho SB (2012) DAPk1 inhibits NF-κB activation through TNF-α and INF-γ-induced apoptosis. Cell Signal 24:1471–1477CrossRefPubMedGoogle Scholar
  30. 30.
    Liu AQ, Ge LY, Lu XL, Luo XL, Cai YL, Ye XQ, Geng FF (2014) Silencing of the hTERT gene by shRNA inhibits colon cancer SW480 cell growth in vitro and in vivo. PLoS One 10(9):e107019. doi: 10.1371/journal.pone.0107019 CrossRefGoogle Scholar
  31. 31.
    Shi YA, Zhao Q, Zhang LH, Du W, Wang XY, He X, Wu S, Li YL (2014) Knockdown of hTERT by siRNA inhibits cervical cancer cell growth in vitro and in vivo. Int J Oncol 45:1216–1224PubMedGoogle Scholar
  32. 32.
    Tu CC, Kumar VB, Day CH, Kuo WW, Yeh SP, Chen RJ, Liao CR, Chen HY, Tsai FJ, Wu WJ, Huang CY (2013) Estrogen receptor α (ESR1) over-expression mediated apoptosis in Hep3B cells by binding with SP1 proteins. J Mol Endocrinol 51(1):203–212CrossRefPubMedGoogle Scholar
  33. 33.
    Donninger H, Clark JA, Monaghan MK, Schmidt ML, Vos M, Clark GJ (2014) Cell cycle restriction is more important than apoptosis induction for RASSF1A protein tumor suppression. J Biol Chem 289(45):31287–31295CrossRefPubMedGoogle Scholar
  34. 34.
    Zhong Z, Dong Z, Yang L, Chen X, Gong Z (2013) MicroRNA-31-5p modulates cell cycle by targeting human mutL homolog 1 in human cancer cells. Tumour Biol 34:1959–1965CrossRefPubMedGoogle Scholar
  35. 35.
    Fukuhara S, Chang I, Mitsui Y, Chiyomaru T, Yamamura S, Majid S et al (2014) DNA mismatch repair gene MLH1 induces apoptosis in prostate cancer cells. Oncotarget 30(5):11297–11307Google Scholar

Copyright information

© Springer Science+Business Media New York 2015

Authors and Affiliations

  1. 1.Molecular Pathology Laboratory, Department of Cytology and Gynecological PathologyPostgraduate Institute of Medical Education and ResearchChandigarhIndia

Personalised recommendations